Biology can cut the mass a Mars base must launch by 26 to 85 percent. That range, from a 2025 review in npj Microgravity, is why space agencies are now betting on microbes to make what crews used to fly up from Earth.
Biology turns local CO2, water and regolith into food, plastics and oxygen.
NASA's SynBio program and three 2025-2026 papers show the cell factories already work in simulation.
The bottleneck is no longer the science. It is flight hardware, containment and a mission architecture willing to trust a fermenter.
For thirty years the default plan for living off alien land was physicochemical: electrolyze water, crack CO2, run Sabatier reactors. It works. It is also heavy, power-hungry and stubbornly dependent on parts flown from Earth. A different answer has been maturing in parallel, and it is alive.
What bio-ISRU actually means
In-situ resource utilization (ISRU) is the practice of making what you need from what is already there: regolith, atmospheric CO2, ice. Bio-ISRU adds biology as the factory. Instead of reactors, you fly freeze-dried microbial cell factories and wake them with local water and carbon. The cells self-replicate, run on sunlight or waste, and excrete nutrients, medicines, polymers or propellant precursor.
The appeal is mass. A 2025 review in npj Microgravity estimates biology can cut launched mass by 26 to 85 percent versus conventional abiotic approaches, depending on the product. The wide range is the honest part: simple metabolites sit at the high end, complex polymers at the low end, but even the low end beats flying the equivalent up from Earth. Microbes also close loops: they eat astronaut and process waste and turn it back into useful material, so nothing leaves the cycle.
Mass advantage of bio-ISRU
Estimated reduction in launched mass versus physicochemical ISRU, by product class · npj Microgravity, 2025
Longest in-space bio test
BioNutrients brews on-demand nutrients aboard the ISS across a multi-year experiment · NASA SynBio
Peer-reviewed proof points
Regolith-fed and waste-fed off-world biomanufacturing demonstrated in print since 2025 · Nature Communications, 2025-26
That is the wager.
Growing: the evidence base is accelerating
NASA's Space Synthetic Biology (SynBio) program at Ames has run since 2018. Its BioNutrients experiment, which uses food microorganisms to brew human nutrients on demand, has logged a multi-year flight campaign on the ISS and is approaching completion. The agency's CO2-Based Manufacturing work chemically converts CO2 and water into media that then feeds engineered organisms, producing food, medicines and even plastics.
Academia caught up fast. A 2025 Nature Communications paper introduced AF-ISM, alternative feedstock-driven in-situ biomanufacturing, which grows the hardy bacterium Rhodococcus on lunar and Martian regolith simulant plus reclaimed waste, producing lycopene without Earth-supplied minerals. A 2026 Nano-Micro Letters review on extraplanetary chemical and biological materials technologies extends the idea toward microbial protein production for long-duration habitation. ESA's 2023 SciSpace white paper, turned into a 2025 npj Microgravity review, framed the whole field around four pillars: ISRU, life support, radiation protection and health.
The cadence is the signal. A 2023 white paper became a 2025 review, which sat beside a 2025 regolith-fed demonstration and a 2026 extraplanetary-materials review. The field moved from opinion to reproducible result in three years, and a 2026 review on extraplanetary chemical and biological materials technologies now treats bio-ISRU as one strand of a wider make-it-there push. That is how a frontier goes from interesting to investable: not one breakthrough, but a stack of them arriving close together. None of it is flight-qualified yet, and that gap is exactly where the risk and the upside both live.
As we covered this week with LanzaTech's carbon-recycling barge, engineered microbes turning CO2 into saleable product are already at commercial scale on Earth. The same logic is now being aimed at the Moon and Mars.
Falling: why it is still not on the manifest
None of this has flown beyond the BioNutrients nutrient pouch. The cell factories that matter, the ones that make propellant or structural polymer, sit at technology readiness level (TRL) 3 to 5: proven in the flask, unproven as flight hardware. Physicochemical ISRU, by contrast, has already produced oxygen on Mars through MOXIE.
Planetary protection is the quieter wall. A fermenter that leaks onto Martian soil is a contamination event with treaty weight. Any bio-ISRU deployment needs closed-loop containment good enough to satisfy both engineers and the Outer Space Treaty. Throughput is the third problem: a reactor makes product on a schedule; a culture makes product on a doubling time. For a base that needs tons, biology is slow, and the first generation of these cell factories will serve crews, not rockets.
The containment problem is also the product. A bio-ISRU fermenter must be sealed against a hostile environment and against the environment, and it must run for months unattended. That is the same specification a terrestrial biomanufacturer pays for to avoid batch contamination. Space does not invent a new market here. It funds the expensive version of one that already exists, and the cheaper civilian derivative follows.
New: regolith and waste as the feedstock
The 2025 AF-ISM result is the interesting turn. Until then, off-world biomanufacturing still relied on Earth-shipped carbon and minerals. Growing Rhodococcus on regolith simulant plus reclaimed waste removes that last tether: the local body supplies the minerals, the crew supplies the organics, and the loop closes. A 2026 Nano-Micro Letters review on extraplanetary chemical and biological materials technologies treats bio-ISRU as one strand of a wider push to make things where we land, not ship them.
Cell-factory design is where the curve steepens. Synthetic biology now edits metabolic pathways the way software edits functions, so a chassis can be retargeted from nutrients to propellant precursor to polymer without rebuilding the hardware. The same AI-assisted strain design that is reshaping industrial biomanufacturing on Earth is now pointed at the payload problem in space.
The propellant prize
The reason agencies take bio-ISRU seriously is the return trip. A Mars ascent vehicle needs propellant, and flying it from Earth doubles the mass of the entire campaign. The 2025 Nature Communications paper on AF-ISM notes that bio-ISRU has been proposed for a Mars-specific rocket propellant, 2,3-butanediol, brewed from local CO2, sunlight and water through engineered bacteria, and that a bio-ISRU route for that molecule uses 32 percent less power than proposed chemical strategies. No flight demo exists. But the pathway from flask to Mars is now a published engineering case, not a thought experiment.
For an investor, propellant is the lever. Food and medicines save mass. Propellant saves the mission. Whoever owns the closed-containment cell factory that can be retargeted from nutrient to propellant precursor owns the part of the architecture that is hardest to fly and easiest to license back on Earth.
Bio-ISRU versus the Sabatier baseline
| Parameter | Bio-ISRU | Physicochemical ISRU |
|---|---|---|
| Launch mass | ✔ Lower (self-replicating, 26-85% saving) | ✗ Higher (reactors, power, catalysts) |
| Energy demand | ✔ Low, runs on sunlight or waste | ✗ High (electrolysis, heating) |
| Maturity (TRL) | ✗ 3-5, flask-stage | ✔ 6-9, flown (MOXIE) |
| Loop closure | ✔ Eats waste, reclaims material | ✗ Linear, resupply-dependent |
Signals to track
First flight demo of a non-nutrient bio product beyond BioNutrients.
A crewed architecture (Artemis, Mars) that names biology in its ISRU plan.
Commercial biofoundry interest in space-grade, closed-containment hardware.
Planetary-protection rules that explicitly permit contained bio-ISRU.
Why investors should care
The near-term money is not on Mars. It is on the terrestrial spillover. Every advance in off-world biomanufacturing, low-energy cell factories, closed-loop containment, regolith-derived media, feeds the same circular bioeconomy investors are already backing in carbon recycling and industrial fermentation. Space is the stress test that makes those tools cheaper and tougher. The base is small. The licensing is not.
The pattern repeats across hard tech. A demanding customer, here a space agency, funds the hard version, and a civilian market absorbs the cheaper derivative. Radiation-hardened parts, synthetic lubricants and closed-loop life support all followed that path. Bio-ISRU is early, but the derivative market, contained industrial fermentation that needs no resupply, is already large and growing. The capability that brews nutrients on a Martian plain is the same capability that brews them in a remote terrestrial plant with no cold chain.
The bet, stated plainly
Bio-ISRU will not replace reactors. It will sit beside them, taking the products reactors are bad at: living compounds, slow chemistry, things that improve when the factory copies itself. The investment case is not a Mars base by 2035. It is the steady transfer of space-grade biomanufacturing tools into a terrestrial bioeconomy that already pays for them. Watch the flight demos. Watch the containment hardware. Watch the first architecture that names biology in its ISRU plan. Each one moves the date. The gap between flask and flight is the whole opportunity.
